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Executive summary 
 
For a country like Bangladesh, pharmaceutical sector is a great success story. The market is 
growing in a spectacular rate. In just five years (from 2010 to 2014) the size of the market almost 
doubled. Competition is fierce in the market, but since growth potential is still there the 
pharmaceutical companies are exerting their best effort to gain more market share and be a part 
of the growth. Sanofi-Aventis Bangladesh Limited is no exception. Along with other strategies 
like bringing up their own research product to Bangladesh market, they are also trying to win 
greater share of the generic market. Launching dermatological product portfolio was a decision 
in congruence to their growth policy. This report was prepared as an internship report to fulfill 
the program completion requirement of the BBA Program at BRAC University and the training 
work was done in Sanofi-Aventis Bangladesh Limited. In the training program, firsthand 
experience was gained regarding pharmaceutical product launch by working in the derma 
portfolio launching project. The intention of the internship training was to obtain some real 
world experience by working in a practical environment. Pharmaceutical marketing is a delicate 
task, product launching is even more. It is such a complex task that, for every marketer in the 
pharmaceutical sector it’s a challenging experience. The Inter-departmental nature of the jobs 
makes it extremely interactive. The product manager has to manage so many stakeholders that he 
has to be very careful about maintaining the balance. Beginning from the initial market analysis 
and profit-loss analysis, thorough subjective and objective decision making capabilities are 
required. Meeting the deadline is always important but it becomes more so in case of product 
launching. An efficient communication line has to be maintained between the backward linkage 
stakeholders (supply chain & production) to the forward linkage stake holders (distribution & 
sales). Also the task of managing external stakeholders, like vendor management, is involved in 
many steps of launching. The task of launching a pharmaceutical product is critical in the sense 
that, for the company, it is a step forward to capitalize growth opportunities. Launching is also a 
critical experience for a product manager: it requires interaction with almost every department of 
a pharmaceutical company. This is probably the best way of getting an in-depth understanding of 
the pharmaceutical marketing job. Being involved in the product launch procedure at Sanofi-
Aventis Bangladesh Limited was an enriching experience. 
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1 Introduction 
1.1 Background 
Pharmaceutical sector is one of the most thriving sectors in Bangladesh. The 1982 drug 
ordinance directed the whole industry in such a favorable direction that in the recent years 
Bangladesh is almost self sufficient in producing medicine. The local drug manufacturers 
flourished in the last three decades, displacing the multinational pharmaceutical companies form 
the leading position in the market. The multinational companies are fighting back with a better 
value proposition and continuing to offer new products. Even though the competition is fierce, 
the consumers are being benefitted by theses healthy competition among the local and global 
companies. 
 
Being one of the leading multinational pharmaceutical companies operating in Bangladesh, 
Sanofi-Aventis Bangladesh Limited is exerting its best effort to become one of the top 5 
companies in the country. The company is making new launching of originator products and also 
generic products to stay in line with the market dynamics. This report is the study of an 
upcoming product of Sanofi-Aventis Bangladesh Limited. The new launch ‘Comol’ has been 
subjected to study to observe and analyze the launching procedure of a pharmaceutical product. 
 
1.2 Origin of the report 
 
This report was prepared as an internship report to fulfill the program completion requirement of 
the BBA Program at BRAC University. The report was completed on the proposed topic 
"Pharmaceutical product launching: A Sanofi-Aventis Report". 
The intention was to gain some real world experience by working in a practical environment. 
The internship supervisor was Dr. Imtiaz Ahmed Firoz, Manager CNS-Derma Business, Sanofi-
Aventis Bangladesh Limited and the faculty advisor was Mr. Mohammad Rezaur Razzak, 
Associate Professor and Director of Centre for Entrepreneurship Development (CED), BRAC 
Business School. 
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1.3 Objective of the report 
 
The objective of this report was to find answers to the following questions: 
· How new product feasibility study is done in a pharmaceutical company? 
· How product launch plan is formulate? 
· How the product launching plan is executed? 
· What are the findings and analysis? 
· What will be the recommendations? 
 
The outcome of the thorough study done during the internship period has been represented and 
consolidated in this report to fulfill the objective of the report. 
 
1.4 Scope of the report 
 
This report studies a single product: ‘Comol’ of the upcoming derma portfolio of Sanofi-Aventis 
Bangladesh Limited. The observation period of the report is from February 15, 2014 to May 15, 
2014. 
1.5 Methodology 
 
The report has been prepared on the basis of primary data collected from the real life activity and 
secondary data collected from publications, and internet. 
The collected data were analyzed and consolidated. The data analysis procedure endorsed by the 
company has been used to analyze data for the report. 
 
1.6 Limitations 
 
In some instances, actual numerical figures were not presented in the report due to 
confidentiality issues. 
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2 Overview 
2.1 Industry Overview 
 
Pharmaceutical sector is technologically the most developed manufacturing industry in 
Bangladesh and the third largest industry in terms of contribution to government’s revenue. The 
industry contributes about 1% of the total GDP. There are about 250 licensed pharmaceutical 
manufacturers in the country; however, currently a little over 100 companies are in operation. It 
is highly concentrated as top 20 companies produce 85% of the revenue. According to IMS, a 
US-based market research firm, the retail market size is estimated to be around BDT 84 billion 
as on 2011. 
 
Two organizations, one government (Directorate of Drug Administration) and one semi-
government (Pharmacy Council of Bangladesh), control pharmacy practice in Bangladesh. The 
Bangladesh Pharmaceutical Society is affiliated with international organizations International 
Pharmaceutical Federation and Commonwealth Pharmaceutical Association. 
 
Bangladesh pharmaceutical companied focus primarily on branded generic final formulations, 
mostly using imported APIs (Active Pharmaceuticals Ingredient). Branded generics are a 
category of drugs, including prescription products, that are either novel dosage forms of off-
patent products produced by a manufacturer that is not the originator of the molecule, or a 
molecule copy of an off-patent product with a trade name. About 85% of the drugs sold in 
Bangladesh are generics and 15% are patented drugs - the structure differs significantly from the 
international market. Branded generic drugs represent about 25% on average of worldwide 
pharmaceuticals sales’; however, given the popularity in emerging markets like China, India and 
Latin America, branded generic drugs may well dominate the total sales within a decade. 
 
Bangladesh manufactures about 450 generic drugs for 5,300 registered brands which have 8,300 
different forms of dosages and strengths. These include a wide range of products from anti 
ulcerants, flouroquinolones, anti-rheumatic non-steroid drugs, non-narcotic analgesics, 
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antihistamines, and oralanti-diabetic drugs. Some larger firms have also started producing anti-
cancer and anti-retroviral drugs. 
Domestic manufacturers account for 97% of the drug sales in the local market while the 
remaining 3% are imported. This is a complete turnaround over from two/three decades back 
when imports used to dominate the market. The imported drugs include essential live saving 
drugs and other high quality drugs. The ratio will further increase in favor of the local production 
as some of the big players are poised to manufacture these high quality drugs in-house in the 
future. 
 
As stated earlier, the size of the retail market reached BDT 84.0 billion as on 2011 based on IMS 
report. The report further stated that, retail sales in the domestic market achieved 23.6% growth 
in 2011 following 23.8% and 16.8% growth in 2010 and 2009 respectively. High growth in the 
last three years (78.8% cumulative and 21.4% CAGR) meant that the Bangladesh Pharmaceutical 
market doubled in just over four years. The retail market also crossed USD 1.0 billion in size in 
2011. It is one of the fastest growing sectors in the country with an annual average growth rate of 
17.2% over the last five years and 13.1% over the last decade. 
 
However, considering that IMS does not include rural market in their survey, the actual size of 
the market will vary slightly (5%-10%). It is estimated that the retail market represent 90% of the 
total market; in that respect the total market size (including the rural market) is expected to be 
over BDT 90.0 billion at present. 
 
Government spending proportion is much lower than that in other regions - it is one possible area 
where future growth may come from. Moreover, the total health expenditure to GDP ratio and 
health expenditure per capita of Bangladesh (both of which gradually increased from 2000) is 
very low in comparison to developed and developing countries. Since the base is still very low, 
we expect the recent growth in the local retail market to continue in the current decade. Some 
other factors that will also boost the industry growth include: 
· Increase in number of modern hospitals 
· Increase in level of service/treatment provided in the hospitals with improved/more     
modern diagnostic equipments 
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· General people are getting more health conscious 
· Growing income level of the people 
· Export of pharmaceutical products 
 
Based on the IMS report for the fourth quarter 2011, Square Pharmaceuticals (DSE: 
SQURPHARMA) holds the top market share in the retail market - 18.7%, followed by Incepta 
Pharmaceuticals (INCEPTA) - 9.3%, Beximco Pharmaceuticals (DSE: BXPHARMA) - 8.8%, 
OpsoninPharma (OPSONIN) - 5.1% and Renata (DSE: RENATA) - 4.9%. The top five 
companies held 46.8% market share in 2011, slightly more than their 46.2% market holding in 
2010 - indicating cumulative revenue growth in excess of the sector growth. Among the top five, 
three are listed in DSE – Square, Beximco and Renata. 
 
 
Top 10 companies held 67.7% of the market in 2011 as shown in chart 1. Growth at par with the 
entire market meant that there cumulative holding did not change from 2010 level. However, the 
market share shifted among the top players. SQURPHARMA lost 0.5% market share in the last 
year (from 19.2% in 2010) while the next four companies gained 1.1% market share in the same 
period. Growth in local sales of these four companies – INCEPTA, BXPHARMA, OPSONIN 
and RENATA – was 28.5% in 2011, increasing their market share from 27.0% in 2010 to 28.1% 
in 2011. 
 
2.2 Sanofi Worldwide 
 
Sanofi, a leading global pharmaceutical company, discovers, develops and distributes therapeutic 
solutions. Sanofi is the one of world’s leading Pharmaceutical companies and the largest in 
Europe. Present in more than 100 countries, with around 11,000 scientists, Sanofi has around 
100,000 employees working to improve health and wellbeing. The Global headquarters are in 
Paris, France 
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Sanofi focuses its activities on 7 major therapeutic areas: 
• Cardiovascular 
• Thrombosis 
• Oncology 
• Central Nervous System 
• Metabolic Disorders 
• Internal Medicine 
• Vaccines 
With more than 25 research centers on three continents, Sanofi coordinates its Research and 
Development on a worldwide basis. The Sanofi annual R&D budget exceeds four billion Euros 
and ranks among the three largest budgets of global pharmaceutical industry. Sanofi currently 
possesses one of the richest and most innovative portfolios in the industry with more than 100 
molecules and vaccines in development, half of which are in advanced stages (phases II and III). 
 
The group dedicates its research in finding innovative, effective and safe medicines that provide 
new therapeutic solutions to patients. 
 
2.3 Sanofi worldwide: timeline 
 
Sanofi is the heir to a long history that includes some of the major scientific advances of the 
nineteenth and twentieth century. In 1718, Laboratories Midy was founded by a family of 
pharmacists. In 1980, the ClinMidy group was acquired by Sanofi. 
 
Laboratories Dausse was founded in 1834 and is Laboratories Robert & Carrière in 1901. They 
merged to create Synthélabo in 1970. In 1860 the pharmacist Etienne Poulenc created 
Wittmannet Poulenc Jeune. And in 1910 it was Rorer’s turn. The two companies eventually 
merged to form Rhône-Poulenc Rorer in 1990. 
 
In 1863, a group of chemists, sales people and workers embarked on the manufacture of dyes in 
a small factory to the west of the town of Höchst in Germany. This was the origin of the 
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company Hoechst, which merged with Roussel (founded in 1911) to form Hoechst Marion 
Roussel. In 1887, Marcel Mérieux, a student of Louis Pasteur, founds the Mérieux Biological 
Institute which, in 2004 became Sanofi Pasteur, the Sanofi’s vaccine division. 
 
The two young groups Sanofi and Synthélabo merged in May 1999 to create a major new 
pharmaceutical player. Sanofi dates back to 1973 and Synthélabo to 1970. In December 1999, 
Rhône-Poulenc and Hoechst Marion Roussel formalized their merger with the creation of the 
Franco-German group Aventis, one of the world’s largest pharmaceutical companies. 
 
In August 2004, Sanofi-Synthelabo acquired Aventis. The takeover was finalized on December 
31 of that year, giving birth to Sanofi-Aventis. On May 6, 2011, Sanofi-Aventis simplified its 
name to Sanofi. 
 
 
2.4 Company Overview: Sanofi-Aventis Bangladesh Ltd. 
 
Sanofi-Aventis Bangladesh Limited is the local affiliate of Sanofi. Sanofi is one of the world’s 
leading pharmaceutical companies which is dedicated to the discovery, development, production 
and distribution of medicines and vaccines, for all people throughout the world. 
 
Sanofi-Aventis is the largest global pharmaceutical company in Bangladesh with a dedicated 
team of more than 1200 employees. 
 
Sanofi-Aventis Bangladesh Limited is the entity that has been formed due to the amalgamation 
of three legal entities- Aventis Limited, Fisons (Bangladesh) Limited and Hoechst Marion 
Roussel Limited. The legal integration process has taken few years after the global merger 
between sanofi-synthalebo and Aventis in 15 September 2004 and finally the existing three legal 
entities have amalgamated as Sanofi-Aventis Bangladesh Limited on December 11, 2007. 
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The head office of Sanofi-Aventis Bangladesh Limited is in Segun Bagicha, Dhaka. The local 
distribution of Sanofi-Aventis products are ensured by 12 sales and distribution offices 
nationwide. 
 
Sanofi-Aventis Bangladesh Limited has a diverse pharmaceutical products includes prescription 
medicines, vaccines and non prescription medicines. Our prescription medicines range across 
therapeutic areas such as anti-bacterial, respiratory, dermatology, oncology, gastro- intestinal, 
cardiovascular and other diseases. The company is the market leader in most of the therapeutic 
categories in which it operates. 
They offer a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease 
caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus and others. 
 
Locally, sanofi-aventis encompasses Sanofi Pasteur, a world leader in vaccines. In Bangladesh, 
vaccines like TetavaxTM, VerorabTM, Euvax BTM, AvaximTM, ACT-HIBTM, 
TyphimViTMetc are included in the portfolio. 
 
 
3 Responsibilities during internship 
 
The internship program was started on February 15, 2014. The internship was to last for three (3) 
months and as a result the internship period came to an end on May 15, 2014. 
 
Sanofi-Aventis Bangladesh Limited was planning to launch a new product portfolio in 2014, 
consisting of only dermatological products. The author of this report was assigned to the derma 
new launch project and this report is based on the experience obtained there. The major brand of 
the derma portfolio, ‘Comol’ (active pharmaceutical ingredient: Clobetasol propionate) was 
decided to be the brand of interest of this report. 
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4 Product Overview 
4.1 Product 
 
One of the upcoming products of Sanofi-Aventis Bangladesh Ltd.: ‘Comol’, is the subject of 
interest of this report. 
 
Figure 1: Brand logo 
 
The product is scheduled to be launched on February 2014. Details of the brand are given 
bellow: 
 
 
Criteria Details 
Therapeutic class TOP CORTICOSTEROIDS PLAIN 
IMS Code D07A 
Original company / brand GSK- Dermovate 
Product type Corticosteroid 
Indications 
Short-term treatment of severe resistant inflammatory 
Skin disorder 
Dosage, strength & pack sizes 0.05% cream /ointment (10g tube) 
No. of Clobetasol brands Seventeen (17) 
Market size 159,814 K BDT (24% growth over 2010) 
 
Table 1: Product details 
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4.2 Competitors’ Products 
 
There are currently 17 other cobetasol brand present in the market, which are the direct 
competitors of the brand ‘Comol’. The major competitors are as follows: 
 
Brand 
Name 
Generic 
Name 
Company Presentation 
 
Pack Size 
 
Dermovate 
Clobetasol 
proprionate 
0.05% 
 
GSK 
Cream 10gm 
Ointment 10gm 
Dermasol 
Clobetasol 
propionate 
0.05% 
 
Square 
Cream 10gm 
Cream 20gm 
Ointment 10gm 
Ointment 20gm 
Nyclobate 
Clobetasol 
0.05% 
Incepta 
Cream 10gm 
Ointment 10gm 
 
Table 2: Major competitors 
 
5 Launch Planning 
5.1 Launch Planning at Sanofi-Aventis 
 
The initiation point of product launching at Sanofi-Aventis is the NPC (New Product 
Committee). This committee is headed by the Managing director and consists of the following 
members: Director Business Operations, Director Specialty Business, Director Business 
Excellence, Director Supply Chain, and Director Industrial Affairs. 
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This committee continuously analyzes the market information and explores the potential of new 
products. Any proposal of new launch is initiated by a NPC member in its meeting. If any 
molecules seem significantly potential in the primary analysis then it is preceded for feasibility 
analysis. 
 
5.2 Market analysis 
 
Based on the available IMS data, market analysis has been done and projection has been done for 
‘Comol’ up to year 2015: 
 
 
 
 
This is a primary analysis and the forecast will be adjusted after launching in accordance with 
market dynamics, product performance and sales force size. 
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5.3 Profit and loss analysis 
 
Based on Sanofi-Aventis internal standard, profit and loss analysis has been done. The analysis 
shows that product contribution will be positive from year two of launching. 
 
Before launching a product, profit and loss analysis is done using the internally standardized 
format. To assess the potential of a product, a factor called “Product contribution” is calculated. 
This factor indicates how launching of a new product will affect the ongoing business. For the 
first one or two years if a newly launched product contributions with a negative product 
contribution value, it could be tolerated, given that in the long run (from year 2/3 and onwards) 
the product will contribute with a significant positive product contribution value. It is expected 
that in around 5th year of launching the product with contribute with a contribution value of 
around 50%. This analysis has been done for the brand ‘Comol’ and it has been found that in the 
first year of launch the product contribution will be negative and in the second year after 
launching the contribution will be significantly low. But then gradually it will increase to gain a 
value of around 50% in the fifth year. This analysis shows that the viable option to gain positive 
product contribution in the long run. The sample calculation presented in this report assumes an 
introductory sales line of 6 sales people and considering the initial R&D expense gives us an 
approximate idea of the profit and loss scenario of the newly launched product. 
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5.4 Go-No Go decision 
 
The market analysis of the molecule clobetasol showed that it has a significant market volume in 
Bangladesh and has a strong growth prospect. Based on the profit and loss analysis it found out 
that the clobetasol brand will contribute positively to the business. This elaborate analysis 
enabled the NPC to decide ‘GO’ for a clobetasol brand and the launching responsibility was 
handed over to the marketing team PCB. The brand name was set to be ‘Comol’. 
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5.5 Pricing and Forecast 
 
Pricing of the product is done considering two factors: Gross Profit and competitor’s price. 
Considering the competitors price, the price of a newly launched product is set in such a way that 
it would contribute at least 50% gross profit. Significantly higher or lower price than the 
competitors is highly uncommon in pharmaceutical industry. Only in case of some premium or 
originators products, price is set at a premium. Since ‘Comol’ is neither a premium product nor 
an originator’s product, the conventional pricing policy was utilized to set the brand’s price. The 
two input factors: COGS and competitors price was he determining parameters here. The price 
while set equal to the competitors’ price showed to generate significant gross profit. Through 
elaborate calculation of differing price and yielding gross profit, it was finally decided that the 
price will not be varied from that of the competitors. The finally decided price of ‘Comol’ is as 
follows: 
Brand Name Presentation MRP/Pack TP/Pack 
Comol 
Cream 10gm 58 43.61 
Ointment 10gm 68 51.13 
 
Table 5: Pricing 
 
While fixing the price, a primary forecast has been done by the marketing department for the 
brand: 
 
    2014 2015 2016 2017 2018 
Brand 
Name 
Presentation Vol Val Vol Val Vol Val Vol Val Vol Val 
Comol 
Cream 10gm 60 2617 80 3489 104 4535 130 5669 156 6803 
Ointment 
10gm 
10 511 
70 3579 91 
4653 
114 5816 137 6979 
* volume in K 
 Unit, ** value in K BDT  
 
Table 6: Five year forecast 
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5.6 Budget allocation 
 
The first step of allocating expense budget is to determine the sales budget of a product. Each 
year a sales budget is set to be achieved by the business unit. This sales budget acts as the target 
to be achieved and set by the product manager. This sales budget is then reviewed and finalized 
after feasibility assessment and the business operations head approves the final sales budget. 
Depending on the targeted sales budget, AnP budget (Advertising and Promotion budget) is 
allotted for a product. The brand ‘Comol’ is not a budgeted product in 2014, meaning it does not 
have any targeted sales budget which is to be achieved in 2014. So the expense budget cannot be 
allocated based on sales budget. Since it’s a new launch, special approval expense budget has 
been allocated for the brand to start promotion in 2014. Form year 2015 and onwards, ‘Comol’ 
will be a budgeted product (i.e. will have a sales budget, which will have to be achieved by the 
business unit) and will have expense budget allocated on the basis of that sales budget. 
 
 
6 Pre-launch Activities 
 
6.1 Marketing Strategy 
 
A marketing strategy framework was developed for the product ‘Comol’. Listed below are the 
steps of the marketing strategy framework: 
 
Step 1: Background studies 
Through background studies were done to access the necessity of dermatological product of 
topical corticosteroid therapeutic class 
 
Step 2: Situation Analysis (SWOT) 
SWOT analysis helps to identify the opportunities and challenges in the derma market. 
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Step 3: Target Audiences 
Target audience is identified to consolidate the customer base and develop the proper marketing 
policies. 
 
Step 4: Marketing Goals 
Based on the background analysis, situation analysis and target audience analysis, marketing 
goals were set. 
 
Step 5: STP (Segmentation-Targeting-Positioning) 
Segmentation and targeting was done with through data analysis. Proper positioning was done 
keeping the target market and consumers in mind. 
 
Step 6: Development of promotional plan 
After executing STP exercise, a through promotional plan was developed to convey the 
positioning statement to the mind of the targeted customers. 
 
 
6.2 Analyzing customer base 
 
Pharmaceutical products are different from other products (like FMCG products) in several 
ways. Among other aspects, customer base is one of the major differentiating factors. In 
pharmaceutical industry the buyers of the products are not the target-customers of the 
pharmaceutical companies, the prescribers are. After diagnosing the disease the Physicians 
prescribes the drug to the patients. In Bangladesh, physicians are free to prescribe any brand of a 
drug molecule appropriate to the patient’s pathological condition. If a patient is diagnosed with 
fever, a doctor can prescribe any brand of metronidazole (i.e. Flazyl or Flamid) to that particular 
patient, as long as he thinks that molecule is the appropriate medicine for the patient. The patient 
then goes to the chemist shop/pharmacy with the prescription and the pharmacist/chemist fills 
the prescription with the brand of the drug prescribed by the physician. From this scenario it is 
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evident that the physician directly influences the sales of the brand but the actual purchase is 
done by the patient. In most of the cases the patient or the pharmacist does not change the brand 
of the medicine while the actual sale occurs. Exception is observed only in case of some OTC 
(over the counter) drugs, brand substitution may occur there. 
 
This dynamics must be kept in mind while doing the customer base analysis for any 
pharmaceutical brand. The brand of interest of this report, ‘Comol’ is a prescription medicine 
and its’ highly unlikely that prescription substitution will occur in its prescribing-selling process. 
That is why; analyzing the prescriber base of the molecule of ‘Comol’ was considered as the 
appropriate way of getting a clear idea of the Brands customer base.  
 
To analyze the customer base, prescription data obtained from a pharmaceutical market research 
firm: 4P marketing consultancy was used. 4P marketing consultancy provides weekly 
prescription survey data to its clients. Sanofi-Aventis is a client of 4P marketing consultancy and 
gets prescription survey data from them on a periodic basis. The market research wing of the 
business excellence department of Sanofi analyzes the data in accordance with the need of the 
business units and disseminates the report to all the BUs. 
 
 The derma project also gets the prescription survey data on all existing brands of clobetasol in a 
weekly basis. This database was utilized to generate target customer analysis report. A one year 
time period (april 2013 to march 2014) was chosen to be the time frame. The report consisted of 
around 17000 instances of prescription generation of the relevant brands. From there, 5000 
unique doctors were identified and most potential 500 doctors were arranged in a pool to be 
targeted. This primary report was circulated to the existing sales line of the Sanofi primary care 
business to verify the details and address of the target physicians. The Regional Sales Managers 
were allowed to add or subtract name and details of the potential physicians not mentioned in the 
report, provided that the number of the addition or subtraction will not exceed 10% of the list 
provide. After receiving the revised list from the regional sales managers, the segmented data 
base was consolidated to finalize the target doctors. 
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6.3 Segmentation 
 
The most potential prescribers of the molecule, clobetasol (the active pharmaceutical ingredient 
of the brand ‘Comol’) were analyzed for doctor specialty distribution. The data was analyzed to 
find out the number of doctors in each specialty segment for the 500 baseline prescribers. From 
among them the most and the least potential segments were identified. It was observed that the 
skin and the pediatrics specialty are the most potential segments and the cardio and surgery 
segments are lest potential segments. 
 
6.4 Targeting 
 
From among the segments, the most potential ones were targeted and the least potentials were 
excluded. To sustain the 500 baseline prescribers, more doctors for the targeted segments were 
added from the database. The targeting scheme makes the orientation more focused and it will 
make it easier to position the products in the targeted segments. The targeted doctors segments of 
‘Comol’ are the skin specialists and the child specialists. 
 
6.5 Positioning 
 
Positioning means the perception build in the mind of the customer about the product. For the 
product ‘Comol’, the task of positioning was a tricky one. Since there is a very well established 
brand: Dermovate, is dominating the market, it was necessary to give a simple and precise 
message to the targeted customer base to develop perception about the brand. It was decided to 
do the positioning as follows: 
“Effective and safe option for psoriasis management” 
The specific disease class was targeted and ‘Comol’ was positioned as the effective and safe 
option to manage psoriasis. 
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6.6 Planning and Developing Promotional Material 
Planning and developing promotional material is a very critical step in pharmaceutical 
marketing. In case of a launching product, the importance is further stretched since the launching 
promotional materials are supposed to create the buzz among the target customers, who are 
habituated to prescribe other brands. For the upcoming brand ‘Comol’, printed promotional 
materials have been developed for the launching month. Printed promotional materials include 
literature, drop card, slip pad, leaflet and scientific journal article. 
 
Printed 
Description 
promotional 
material for 
‘Comol’ 
  
Product literature 
Contains basic scientific information regarding the disease, scientific study 
demonstrating the drug’s potential & safety profile, pack info, prescribing 
info. Contains brand logo 
Product drop card 
Contains all the info contained in a product literature in a concise form. 
Contains brand logo 
Slip pad 
Prescribing pad containing very brief information. Contains brand 
Logo 
Leaflet 
Contains overview of and guideline to the disease management. May 
contain brand logo 
Scientific journal 
article 
Journal article concerning the disease 
 
Table 7: Promotional materials 
 
Each and every promotional material has to go through two different scrutiny processes. 
Internally the Medical and regulatory affairs department of sanofi-aventis accesses the rationale 
and appropriateness of the promotional material. Then each one has to be approved by the 
national regulatory body: the Drug Administration. 
 
  
 21 
 
All the promotional materials prepare for ‘Comol’ has undergone this process and all of them are 
finally approved to be circulated among the target doctors. 
6.7 Field Force Deployment 
 
Field force deployment planning was done in accordance with geographic distribution of the 
target customers. The sales line which will execute the sales activity of the brand ‘Comol’ is the 
derma sales line. This will be the sales line dedicated to all dermatological brands among which 
‘Comol’ is the flagship brand. 
 
Region Number of 
target doctors 
 
Number of 
sales reps 
 
Dhaka I 150 3 
Dhaka II 100 2 
Chittagong 50 1 
Comilla 50 1 
Sylhet 50 1 
Bogra 50 1 
Khulna 50 1 
Total 500 10 
 
Table 8: Field Force Depolyment 
 
 
In 2013, the derma sales line representatives will be appropriated from and existing sales line of 
Sanofi-Aventis: the Primary care sales line. This sales line is divided in 7 regions country wide, 
having a regional sales manager for each region.  
 
The newly appointed sales reps will be reporting to the respective PC-national regional sales 
manager of his respective region. The Derma business unit will not directly supervise the sales 
activity. The number of target doctors is not equally distributed among all the regions, in highly 
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potential regions like Dhaka-1 and Dhaka-2 the number of target doctors is more than the other 
regions. 
 
 A single sales representative will be appointed to cover 50 target doctors. According to this 
policy, Dhaka-I will have 3 reps, Dhaka-II will have 2 reps and all other regions will have a 
single rep to cover the target doctors. In total, 10 reps will constitute the derma sales line in the 
launching year (2014). Potential sales reps among the existing regions are being interviewed to 
be deployed to the derma sales line. The vacancies created by the transfer of reps from the 
existing sales line will be filled up by new recruits. Since, derma sales line will promote a whole 
new portfolio, the experienced sales reps are being transferred from other sales line rather than 
appointing new recruits. 
 
6.8 Developing Training Material 
 
Before launching of any new product, a very important step is to train the sales force properly. If 
a new product is similar to any existing product (i.e. of the same therapeutic class) it’s easier to 
execute the training task since the reps are acquainted with the details of the therapeutic class and 
associated diseases. Thus training procedure of a newly launched antibiotic will be much easier 
since there are many existing antibiotic products being actively promoted. But the task becomes 
harder if a pharmaceutical product is of a novel therapeutic class.  
 
Since, Sanofi-Aventis is currently not doing active promotion of any dermatological products, 
sales reps are not acquainted with this type of products. This makes the training process is of 
much importance for the derma sales line. 
 
There are two standard training materials which are developed for each and every launching 
product. These are as follows: 
 
 Training manual and presentation 
 Brand book 
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Training manual: 
 
The training manual is a comprehensive guideline to the sales representative. This manual covers 
a vast array of topics, ranging from basic physiological facts to market details. The manual 
usually consists of two parts: the disease part and the product part. For the product ‘Comol’ the 
details of the training manual is as follows: 
 
Topics Covered In case of the brand ‘Comol’ 
Disease part  
Physiology Skin structure and function 
Common diseases Common disorders of skin 
Overview of the disease Overview of Eczema and Psoriasis 
Detailed discussion Details on Eczema 
 Details on Eczema treatment 
 Details on clobetasol (brand: Comol) in Eczema 
 Details on clobetasol (brand: Comol) in Psoriasis 
 
Product part  
Product details Price, SKU, Availability 
Market details Competitors’ products, market scenario, market dynamics 
Target customers Customer base analysis 
STP Segmentation-targeting-positioning 
Marketing strategy Product specific marketing strategy 
 
Table 9: Segments of training manual 
 
 
Based on the training manual a training presentation is prepared which is used in the training 
sessions of the sales reps. 
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Brand book: 
 
Another important training material is the brand book. The brand book is based on the printed 
promotional materials. A brand book has been developed for the launching product ‘Comol’. In 
the printed promotional material the scientific information is presented in a concise manner with 
aiding visual. In the brand book content of the printed promotional materials are elaborated. The 
sales reps make call to the doctors to promote the product and the brand books contains 
instruction covering every aspect of a call. It instructs how to approach the doctor, how to detail 
the printed promotional material and how to engage the doctor. Probable objections by the 
doctors are also discussed in the brand book. The common aspects covered in the brand book 
are: 
 
Section of Brand 
Book 
 
Purpose 
 
Patient identification To identify the correct patient 
Call openers To attract the attention of the doctor to the product 
Interview questions To comprehend doctors attitude toward the product 
and associated disease 
Demonstrate capability To inform the efficacy of the product 
Validation question To identify whether the message is clear to doctor or 
not 
Closing questions To win doctor's support for the product 
Objection handling To handle any objections raised by the doctor 
  
Table 10: Segments of Brand Book 
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A snapshot of the brand book developed for ‘Comol’ is presented here”: 
 
 
Figure 3: Brand Book sanpshot 
 
 
 
7 Launching 
 
When price is approved by the drug administration, factory is ready to manufacture and all the 
promotional material are finalized then the actual launching operation is initiated. For the brand 
‘Comol’, this launching operation will be initiated in the second week of August 2014. There are 
several steps in the launching operation. These steps are discussed here: 
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7.1 Training program for the sales forces 
 
For every sales line, monthly meeting is held in the beginning of each month. For the derma 
sales line the first such meeting will be held on the beginning of the launching month (tentative 
date: August 1, 2014). In this meeting the training of the sales forces will be conducted. Based on 
the training manual developed, the marketing department will provide training on the following 
modules: 
- Product overview 
- Market overview 
- Scientific details of the product 
- Marketing and sales strategies 
In collaboration with the marketing department, the ‘Sales force training department’ will 
provide training on sales techniques. 
 
7.2 Pipeline filling 
 
After the factory produces the first batch of the product, the product manager of the marketing 
department finalizes the allocation of product to the 13 depots of Sanofi-Aventis all around the 
country. The allocation is based on the geographic distribution of the target customers. The sales 
representatives then approach the chemist shops/pharmacies with a launching letter and inform 
them about the product launching. Then according to the demand from the chemists/pharmacists, 
supply is initiated. For Comol this pipeline filling action plan has been finalized. Whenever the 
factory will supply the product, it will be instantly allocated to all the depots and sales personnel 
will start to approach the chemists/pharmacist. 
 
7.3 Initial Communication with target customers 
 
Immediately after executing the pipeline filling task, the first encounter with the target customers 
(the target doctors) takes place. An informative letter is prepared to be delivered to the doctor by 
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the sales reps in person. The doctors’ letter contains the basic information about the launching 
product, the diseases in which it is effective and some other briefings about the product. For 
Comol, the doctors’ letter has been prepared and is scheduled to be distributed to each and every 
one of the 500 target doctor. 
 
 
Figure 4: Doctors’ letter snapshot 
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In this first meeting the sales representatives will inform the target doctors about the very 
essential information about the product: its molecule, indication, relevant patients and price. 
They will assure the target doctors that the product has been made available in the chemist 
shops/pharmacies and the product will be available to the patients if it’s prescribed. 
 
7.4 Starting the promotional activity 
 
Pipeline filling and initial communication with the target customers will create the ground to 
formally initiate the promotional activity. The promotional activity of ‘Comol’, like all other 
pharmaceutical products, will be done following a monthly plan, called cycle plan. The cycle 
plan clearly defines which promotional activity should be carried out when in a specific month. 
The cycle plan for the launching month of ‘Comol’ has already been developed. To execute the 
cycle plan, target doctors are arranged in three categories according to their prescribing potential: 
 
Category ‘A’ doctors: Most potential 
Category ‘B’ doctors: Medium potential 
Category ‘C’ doctors: Average potential 
 
It has been planned that the category ‘A’ doctors will be visited by the sales representatives eight 
times a month (twice a week). Category ‘B’ and Category ‘C’ doctors will be visited six and four 
times a month respectively. Each visit will deliver at-least a printed promotional material or a 
gift. Each visit will generate a strike to the mind of the doctor about the brand. There is also a 
rough outline of cycle plan developed for the remaining months of 2014. It is expected that the 
promotional activity of the launching month will create awareness of the brand among the 
doctors and analyzing the result the promotional plan of the coming months will be adjusted. 
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8 Post-launching 
 
The post launching activities are out of scope of the report. Only the major activities planned to 
be performed after launching are listed here: 
 
- Performance monitoring in a monthly basis 
- Reviewing the profit loss scenario 
- Sales force right sizing 
- Reviewing the budget acceding to product performance 
 
9 Findings and Analysis 
 
During my 3 month long internship program, I have observed that Sanofi-Aventis faces some 
problems in terms of launching a new product in the market. From my findings, Sanofi faces 
some obstacles when a new product is to be launched as well as some post launching 
complicacy. They are as follows: 
 
1) First of all, when a pharmaceutical company produces various medicines, they need the 
raw materials to produce these. The main ingredients of these medicines can be produced 
in Bangladesh, but other ingredients which are called ‘Excipient’ such as diluents, 
disintegrating agents, binding agents, flavoring agents, sugar etc are needed to be 
imported from USA or France (Mother Company of Sanofi-Aventis). As it takes time, 
the entire launching plans delay. Other local pharmaceutical companies import these 
ingredients from India and China at a lower cost. But multi-national companies like 
Sanofi are bound to obey the rules. 
2) Another problem from my perspective is that Sanofi and other multi-national companies, 
especially pharmaceutical companies, after producing a medicine they put that product in 
a quality control process. After producing any medicine, it will be tested via ‘Shelf Life’ 
process where the medicine will be kept in the shelf for 6 months to check its quality. 
After every three months the quality will be checked. After everything is okay, the 
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product will be ready for launching. The whole process is very time consuming. Most of 
the local companies do not follow these processes. 
3)  When a new product will be launched, pharmaceutical companies especially multi -
national companies need government and many other authorized approvals. These 
processes are slow as well as time consuming in our country. 
4) Pharmaceutical companies often give promotional materials considered as gift items to 
the doctors and chemists. Now some local companies sometimes offer gifts which would 
be considered as unethical. As a matter of fact, some doctors become satisfied with the 
gift despite knowing it is unethical. Multi-national companies like Sanofi have no 
permission to do so which puts them at an unfair disadvantage. 
5) Another minor problem for Sanofi is when a new drug is being produced; drug stores 
refuse to take the new drug until the doctors generate prescriptions. On the other hand 
doctors also become reluctant to prescribe the new drug until it is available in the store. 
So it becomes almost impossible to motivate both of them simultaneously.   
 
 
10 Recommendations 
 
There are some ways to avoid the complicacies which happens when a new product is being 
launched. As I have done a 3 month long internship program at Sanofi and observed their 
launching activities, my recommendations for Sanofi would be: 
 
1. Sanofi’s product launching often delays because of having difficulties in maintaining 
some formalities and multi-national companies have some other criterion. So they 
should make their product launching program well planned through prior negotiation 
and discussion so that the launching program could not be delayed. 
2. The government should make rules and laws in providing gift materials to the doctors 
from the pharmaceutical companies. There will be some certain rules about what types 
of gifts are allowed and what are not allowed for pharmaceutical companies. 
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11 Conclusion 
 
Bangladesh pharmaceutical market is growing in a spectacular rate. In just five years (from 2010 
to 2014) the size of the market almost doubled. Competition is fierce in the market, but since 
growth potential is still there the pharmaceutical companies are exerting their best effort to gain 
more market share and be a part of the growth. Sanofi-Aventis Bangladesh Limited is no 
exception. Along with other strategies like bringing up their own research product to Bangladesh 
market, they are also trying to win greater share of the generic market. Deciding to launch the 
derma portfolio is one big step in gaining a greater foothold in the generic medicine market. 
 
Pharmaceutical marketing is a delicate task, product launching is even more. It is such complex a 
task that, for every marketer in the pharmaceutical sector it’s a challenging experience. The 
interdepartmental nature of the jobs makes it extremely interactive. The product manager has to 
manage so many stake holders that he has to be very careful about maintaining the balance. 
 
Beginning from the initial market analysis and profit-loss analysis, thorough subjective and 
objective decision making capabilities are required. Meeting the deadline is always important but 
it becomes more so in case of product launching. An efficient communication line has to be 
maintained between the backward linkage stakeholders (supply chain & production) to the 
forward linkage stake holders (distribution & sales). Also the task of managing external 
stakeholders, like vendor management, is involved in many steps of launching. 
 
The task of launching a pharmaceutical product is critical in the sense that, for the company, it is 
a step forward to capitalize growth opportunities. Launching is also a critical experience for a 
product manager: it requires interaction with almost every department of a pharmaceutical 
company. This is probably the best way of getting an in-depth understanding of the 
pharmaceutical marketing job. Being involved in the product launch procedure at Sanofi-Aventis 
Bangladesh Limited was an enriching experience. 
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